Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma - Test2 - elhamkhani - TriplyDB

Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma

Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma

http://www.wikidata.org/entity/Q24602657

about

Natural killer cell mediated antibody-dependent cellular cytotoxicity in tumor immunotherapy with therapeutic antibodies Retinoic acid post consolidation therapy for high-risk neuroblastoma patients treated with autologous hematopoietic stem cell transplantation High-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastoma High-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastoma ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma Neuroblastoma Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma Targeted immunotherapy for pediatric solid tumors Involvement of HMGB1 in Resistance to Tumor Vessel-Targeted, Monoclonal Antibody-Based Immunotherapy Translational development of difluoromethylornithine (DFMO) for the treatment of neuroblastoma Cancer Stem Cells and Their Interaction with the Tumor Microenvironment in Neuroblastoma Dysregulated Expression of Glycolipids in Tumor Cells: From Negative Modulator of Anti-tumor Immunity to Promising Targets for Developing Therapeutic Agents Trial Watch: Adoptive cell transfer for oncological indications Immunotherapy of Childhood Sarcomas Enhancing Cancer Immunotherapy Via Activation of Innate Immunity Antibody-based immunotherapy of solid cancers: progress and possibilities NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity in Cancer Immunotherapy Natural killer cells and neuroblastoma: tumor recognition, escape mechanisms, and possible novel immunotherapeutic approaches Approaches to improve tumor accumulation and interactions between monoclonal antibodies and immune cells HDAC inhibitors and immunotherapy; a double edged sword?Trial Watch: Tumor-targeting monoclonal antibodies in cancer therapy Primer on tumor immunology and cancer immunotherapy Neuroblastoma: issues in transplantation Cellular immunotherapy for pediatric solid tumors Children's Oncology Group's 2013 blueprint for research: bone tumors Inhibition of neuroblastoma tumor growth by targeted delivery of microRNA-34a using anti-disialoganglioside GD2 coated nanoparticles In silico Driven Redesign of a Clinically Relevant Antibody for the Treatment of GD2 Positive Tumors The ALK/ROS1 Inhibitor PF-06463922 Overcomes Primary Resistance to Crizotinib in ALK-Driven Neuroblastoma.Protein glycosylation in cancers and its potential therapeutic applications in neuroblastoma Immunological and Translational Aspects of NK Cell-Based Antitumor Immunotherapies TL-118 and gemcitabine drug combination display therapeutic efficacy in a MYCN amplified orthotopic neuroblastoma murine model--evaluation by MRI An Optimized GD2-Targeting Retroviral Cassette for More Potent and Safer Cellular Therapy of Neuroblastoma and Other Cancers Common variation at 6q16 within HACE1 and LIN28B influences susceptibility to neuroblastoma Early phase clinical trials of anticancer agents in children and adolescents - an ITCC perspective.Overview and recent advances in the treatment of neuroblastoma.Tumor-targeted and immune-targeted monoclonal antibodies: Going from passive to active immunotherapy.Safety and efficacy of tandem 131I-metaiodobenzylguanidine infusions in relapsed/refractory neuroblastoma.Anti-GD2 antibody 3F8 and barley-derived (1 → 3),(1 → 4)-β-D-glucan: A Phase I study in patients with chemoresistant neuroblastoma Oxaliplatin and Doxorubicin for relapsed or refractory high-risk neuroblastoma.Pilot study of intravenous melphalan combined with continuous infusion L-S,R-buthionine sulfoximine for children with recurrent neuroblastoma.

P2860

Q21131216-CD2986CC-FEB3-428C-9EE7-EA0DD9D4100F Q24186451-8788D192-F580-4C54-8CFD-F0E566243409 Q24186636-FB2103E5-ABE1-4B60-B61E-38D4A036B646 Q24200296-8082F2AC-70AE-43FE-BBD6-14CAB765228C Q24310296-956C16CC-330A-42D0-BFB9-C233FEC15B41 Q24617733-9329A0C1-F02F-4EEA-98D5-01096D4F6304 Q24630017-4C9E7BC5-D9F0-4D3C-8BA5-86A4A0CDBD67 Q26747703-FAA8F7AE-5C29-4DCE-8D12-70F1FA1AB019 Q26765594-8AC05C32-99D1-40CD-B611-41EED647CA55 Q26770306-A3542A2A-9E1D-4F75-BE55-EC1F0A41B021 Q26771238-DA3AD5C1-3533-49DB-8DFD-6598CF732434 Q26771367-5FCED285-86CC-47EA-97B2-9E4C84161104 Q26785545-86BDD6D0-95B3-4169-825E-6BBE7F37182B Q26795369-9AAF91B5-25D6-41C2-84BF-2A3731AB1BF0 Q26796313-CBB7A2E8-AF09-435B-99ED-D48F61D35AF3 Q26796542-BBFA6988-EDF6-48C5-B2D8-6FF6719BB1DF Q26797345-0791E95C-3A01-425E-8E23-4EE68E81D222 Q26825652-8520F427-3D23-4D36-A6DA-9EAAF4AE6195 Q26852287-1CAAB51C-3D2B-4A4A-855F-5B074DBE0BF5 Q26853102-23F37081-64C2-446C-A792-32FC774391D3 Q26993238-38BAB085-7360-4452-9748-16947C7ED071 Q27001126-D48CF9AC-B5BA-4368-BD24-9C2C2D1DF43D Q27008197-18125C35-D04F-4001-802B-6980170EB31D Q27014912-D3212FCB-5382-49DD-B47E-B3900AB3CD10 Q27027664-50E6F6ED-CFE5-471E-AC8D-43EF3CA194E4 Q27301841-36B24E8B-584A-4F2D-B365-6A689960A896 Q27678257-6A6D509E-70C6-43A5-959D-B2B2651A303D Q27853241-109FE84D-4E6D-4587-8961-32315C33FDEE Q28069952-E021948E-A6F3-48F7-8DA9-12F7625C7C0D Q28079180-3F04B931-5195-4C50-B37B-83B0C870BB64 Q28540575-B15BE0E9-DF26-40BB-A440-32043FE73F09 Q28551080-9851F711-59E3-46B9-837C-89F93E7F4040 Q28943271-9E59A371-AFCF-40FE-9518-DC69385C4933 Q30234441-4993F19C-6250-4CE0-A8A5-C9A4F0DCAE7D Q30238693-8A630804-59B8-4C4D-B062-131B5B30BECB Q30916013-C481875B-5D41-4D04-9694-8E624A4C4077 Q33394925-43812EF1-D99F-4320-8FC9-E39D8218C4EE Q33408675-B9A5779E-5FD7-484A-9595-A745962C328D Q33419558-CAFB8115-9692-4E04-991E-FF2B4402E98F Q33424231-D30D4933-339F-4A53-9A17-4912FA3A8F84

P2860

Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma

http://www.wikidata.org/entity/Q24602657

description

2010 nî lūn-bûn

@nan

2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma

@ast

Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma

@en

Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma

@nl

type

label

Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma

@ast

Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma

@en

Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma

@nl

prefLabel

Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma

@ast

Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma

@en

Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma

@nl

P1433

Q24602657-79906BD6-FE4C-4A5A-9CF4-A0FE57059167

P1476

Q24602657-5E2F9A44-D21C-4C20-B5C7-39B0D7C0B128

P2093

Q24602657-1B197314-B7BD-4340-971C-7BF5F805465E

Q24602657-1ECF90DC-43FB-443D-85FB-D6DF7B8F104B

Q24602657-51AFEA80-4F20-4712-829B-B0A44AFFCBCA

Q24602657-53FB20DA-F8DE-4039-8B65-92466EAC9F0D

Q24602657-630CA7D7-3486-48AF-B9EB-47B4626F7004

Q24602657-66B03AB8-807E-40BD-B24C-48F83153C908

Q24602657-72F5D931-8B2C-40C0-BACE-5D698D214368

Q24602657-81A51C23-575B-4E68-AE8B-97BEEEF6413D

Q24602657-878FE18D-402B-4D34-9F70-86D060D8517E

Q24602657-8E0E92B9-E59B-49F1-B02D-00B12DA9F103

P2860

Q24602657-0E41AF38-16CA-463E-8BD8-3E3E346A9285

Q24602657-1CBD4EC3-513F-4A61-B262-225B27056DD6

Q24602657-216A7BF5-BB9A-47AC-AC19-9A0CEE1AA630

Q24602657-2D5C30A6-F50D-4A73-B40D-1BC76E1FA58F

Q24602657-348E1490-F57D-42E5-A06B-EB4D0B66627B

Q24602657-56B810C8-2034-4633-8C99-5D9429BE1A97

Q24602657-617E9AC4-909D-48FE-83F0-C5343B29AFD5

Q24602657-640CC19C-C3B8-4D27-BDA0-21F2BBA25111

Q24602657-7517FBB3-1112-42B1-875C-2C17CC4618FB

Q24602657-88E3C77E-0AEC-4906-97B2-0D4684261FFA

P304

Q24602657-2A18A553-AAE2-4E13-AEBC-16558B6A4AA4

P31

Q24602657-AB95E27D-BCE3-4BAC-B054-E2C1E139E9E0

P3181

Q24602657-8DF8C9BA-258D-4DCA-9849-13C6756D717D

P356

Q24602657-4DEDA855-0273-4207-A0D3-6AC356CA58A0

P407

Q24602657-8DD8B6BC-F649-4983-8A79-1C4D24215939

P433

Q24602657-F9A06769-CEBB-4B1A-A249-0667D0B2D7F5

P478

Q24602657-DB331489-8FA6-41FE-9D09-042D44E39D3B

P50

Q24602657-22AE03E9-1962-4E61-BF21-B25E252DCA4C

Q24602657-2D93A112-11C3-43CB-B7F9-E541CAAC302D

Q24602657-D76AAABB-CBAE-48B2-B240-043C37D452CF

P577

Q24602657-5F01F0C9-223A-4989-930E-2BA9F68E90B6

P698

Q24602657-9208C573-2232-4B5B-845C-D4EAB85E4499

P921

Q24602657-89fa8c28-b4e1-45db-8065-b28058e857ae

Q24602657-9DE2337E-0C9C-41B6-8C5A-989016AE04E2

P932

Q24602657-3997DC14-770C-463E-A62C-140FE4E9CC32

P3181

P356

P1433

The New England Journal of Medicine

P1476

Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma

@en

P2093

Allen Buxton

http://www.w3.org/2001/XMLSchema#string

Andrew L Gilman

http://www.w3.org/2001/XMLSchema#string

Barry Anderson

http://www.w3.org/2001/XMLSchema#string

Children's Oncology Group

http://www.w3.org/2001/XMLSchema#string

Helen X Chen

http://www.w3.org/2001/XMLSchema#string

Hiro Shimada

http://www.w3.org/2001/XMLSchema#string

John M Maris

http://www.w3.org/2001/XMLSchema#string

Judith G Villablanca

http://www.w3.org/2001/XMLSchema#string

Katherine K Matthay

http://www.w3.org/2001/XMLSchema#string

M Fevzi Ozkaynak

http://www.w3.org/2001/XMLSchema#string

P2860

Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study

A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology Group

Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group.

Consolidation treatment with chimeric anti-GD2-antibody ch14.18 in children older than 1 year with metastatic neuroblastoma.

A phase II trial of trastuzumab in combination with low-dose interleukin-2 (IL-2) in patients (PTS) with metastatic breast cancer (MBC) who have previously failed trastuzumab.

Kidney cancer: the Cytokine Working Group experience (1986-2001): part II. Management of IL-2 toxicity and studies with other cytokines.

Adoptive cell therapy for the treatment of patients with metastatic melanoma.

Phase I study of ch14.18 with granulocyte-macrophage colony-stimulating factor and interleukin-2 in children with neuroblastoma after autologous bone marrow transplantation or stem-cell rescue: a report from the Children's Oncology Group

M2 macrophages phagocytose rituximab-opsonized leukemic targets more efficiently than m1 cells in vitro.

FcgammaRIIIa polymorphisms and cetuximab induced cytotoxicity in squamous cell carcinoma of the head and neck.

P304

1324-1334

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1379277

http://www.w3.org/2001/XMLSchema#string

P356

10.1056/NEJMOA0911123

http://www.w3.org/2001/XMLSchema#string

P407

P433

14

http://www.w3.org/2001/XMLSchema#string

P478

363

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20879881

http://www.w3.org/2001/XMLSchema#string

P921

P932

3086629

http://www.w3.org/2001/XMLSchema#string